Search

Your search keyword '"Arandjelovic, Aleksandra"' showing total 22 results

Search Constraints

Start Over You searched for: Author "Arandjelovic, Aleksandra" Remove constraint Author: "Arandjelovic, Aleksandra" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
22 results on '"Arandjelovic, Aleksandra"'

Search Results

1. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

2. Cardiopoietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial

3. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

4. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

6. The Patterns of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Use in Patients with Atrial Fibrillation in Seven Balkan Countries: a Report from the BALKAN-AF Survey

10. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

11. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial

12. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial

13. Effects of alirocumab on types of myocardial infarction : insights from the ODYSSEY OUTCOMES trial

14. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

15. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

16. Cardiopoietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial.

18. Prognostic value of calcium score and coronary flow velocity reserve in asymptomatic diabetic patients

19. Should procalcitonin be measured routinely in acute decompensated heart failure?

22. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Catalog

Books, media, physical & digital resources